Murphy & Mullick Capital Management’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
Other funds holding NVO
Murphy & Mullick Capital Management's NVO Position: Q3 2026 in Review
Murphy & Mullick Capital Management reduced its Novo Nordisk (NVO) stake by 0.45% in Q3 2026, selling an estimated $1.15K and leaving 5,486 shares worth $208K. The position accounts for 0.13% of the portfolio, ranked #142.
Murphy & Mullick Capital Management first reported a position in NVO in Q4 2024 and has held it in 8 quarters since. The position peaked at $530K in Q4 2024. 1,237 funds tracked by Wall St. Rank hold NVO as of Q3 2026.
- Murphy & Mullick Capital Management held 5,486 shares of Novo Nordisk worth $208K as of Q3 2026.
- Murphy & Mullick Capital Management sold 25 Novo Nordisk shares in Q3 2026, an estimated $1.15K.
- Novo Nordisk made up 0.13% of Murphy & Mullick Capital Management's portfolio in Q3 2026, its #142 holding.
- Murphy & Mullick Capital Management first reported a position in Novo Nordisk in Q4 2024 and has held it in 8 quarters since.
- Murphy & Mullick Capital Management's Novo Nordisk position peaked at $530K in Q4 2024.
- 1,237 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.
Based on Murphy & Mullick Capital Management's 13F filing for Q3 2026, filed 2 Nov 2026.